Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Says its investee company Bio Vitos has received approval from Nasdaq Stockholm to acquire shares in Hemcheck Sweden AB. This follows conditional approval being granted in late August. Bio Vitos will now proceed with completing the transaction, Craven House says. Upon completion, Bio Vitos will own 259.7 million Hemcheck shares, or an 88% stake. Craven House has a 25% stake in Bio Vitos.

Current stock price: $0.23, up 7.1% in London on Monday morning

12-month change: up sharply from $0.11

Copyright 2023 Alliance News Ltd. All Rights Reserved.